PremiumCompany AnnouncementsAdicet Bio Reports Q1 2025 Results and Updates Adicet Bio reports Q1 EPS (31c), consensus (34c) Adicet Bio Appoints Michael Grissinger to Board PremiumCompany AnnouncementsAdicet Bio Advances Clinical Trials and Financial Stability Cautious Hold Rating on Adicet Bio Amid Early-Stage Clinical Developments and Uncertain Outcomes Adicet Bio: Hold Rating Amid Fair Valuation and Awaited Clinical Data PremiumThe FlyAdicet Bio granted fast track designation for ADI-001 by FDA Adicet Bio Advances with Phase 1 Trial of ADI-270 Adicet Bio says 1st patient dosed in Phase1 trial of ADI-270 to treat ccRCC